Genome sequencing company Human Longevity and Freedom Acquisition I have signed a non-binding letter of intent for a business combination. If a deal materializes and is ultimately approved, upon closing the combined company would be expected to remain listed on the NYSE under a new ticker symbol.
Assuming Freedom and HLI enter into the proposed Business Combination Agreement, the parties currently expect to seek approval from Freedom’s shareholders by the first quarter of 2023.
The LOI provides for the new public company to receive $345 million from Freedom’s trust account, less any redemptions by the SPAC’s shareholders. Read more.
